Xgeva Injection

Product Overview

Product Form: Injection
Pack Size: 1 vial (70 mg/1.5 mL)
Prescription Required: Yes

Xgeva Injection

Xgeva Injection is an innovative medication designed to prevent skeletal-related events in patients with bone metastases from solid tumors. Its active ingredient, denosumab, is a fully human monoclonal antibody that effectively inhibits RANKL (Receptor Activator of Nuclear factor Kappa-B Ligand). This mechanism of action helps maintain bone strength and reduces the risk of fractures, pain, and other complications associated with bone metastases. The formulation is sterile and conveniently packaged in a single-use vial, making it easy to administer in a clinical setting.

How Xgeva Injection Works

Xgeva works by binding to RANKL, preventing it from activating osteoclasts — the cells responsible for bone resorption. By inhibiting these cells, Xgeva helps maintain bone density and integrity, significantly reducing the likelihood of skeletal-related events in individuals suffering from advanced cancer.

Xgeva Injection Key Benefits

Major Uses:

- Prevents skeletal-related events in patients with bone metastases. - Reduces the risk of fractures and pain associated with bone metastases. - Supports overall bone health in cancer patients. - Minimizes the need for radiation therapy or surgical interventions related to bone issues. - Can be used in patients with prostate or breast cancer undergoing treatment.

Usage and Safety of Xgeva Injection

Xgeva Injection should be administered by a healthcare professional. The typical dosage is 120 mg every four weeks, with an additional 120 mg given on the first day and at 8 and 15 days after the initial dose. Ensure proper hydration and monitor calcium levels before and during treatment.

Adverse Effects

- Hypocalcemia (low calcium levels) - Fatigue - Nausea - Diarrhea - Back pain

Important Warnings & Precautions

Xgeva carries important safety warnings, including the risk of osteonecrosis of the jaw (ONJ). Patients should maintain good oral hygiene and undergo dental examinations before starting treatment. Additionally, avoid using Xgeva in patients with active infections or hypocalcemia. Regular monitoring of calcium and kidney function is crucial during therapy to ensure patient safety.

Disclaimer

This description provides general information based on our opinion and should not be considered medical advice. Always consult a healthcare professional for personalized guidance regarding medications.